Study on the Occurrence of Head and Neck Cancers During Pregnancy

Status

Suspended

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03738267

Acronym

REFCORbirth

Enrollment

Registered

2018-11-13

Start date

2018-11-07

Completion date

2025-09-23

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer, Pregnancy Related

Brief summary

Head and neck cancers that occurred during pregnancy

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 year old woman or over at the time of participation * PS 0 -2 * Cancer diagnosed (biopsy date) from 01/01/2010 between the second week of pregnancy and the 12 months postpartum. * Primitive may concern the following sites: oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, prevalent lymphadenopathy, nasal cavity, salivary glands, dental tumors, ear tumors, paragangliomas optic pathways, facial sinus / facial mass, nose, ear and other head and neck * All histologies (epithelial tumors, sarcomas, mucosal melanomas, embryonic tumors, undifferentiated tumors) * Patient receiving or having received a specific oncological treatment among surgery, radiotherapy, chemotherapy, hormone therapy. * All stages allowed: localized stages and metastatic stages immediately. * No opposition of the patient to participate in this study

Exclusion criteria

* Any other neoplastic antecedent * Exclusion of metastases at the level of the VADS of another primitive than a cancer of the VADS * Exclusion of hematological tumors (lymphoma) and glial tumors * Person subject to a legal protection measure or unable to express their consent

Design outcomes

Primary

Measure	Time frame	Description
Serological status of patients	Through study completion, an average of 5 years	Number of patients with positive or negative serological status for PVH (Papilloma Virus Humain) and EBV (Epstein-Barr Virus)
Characteristics pregnancy of patients	Through study completion, an average of 5 years	Presence or absence of maternal-fetal diseases
Tumor characteristics of patients	Through study completion, an average of 5 years	Histological type of cancer

Countries

France

Outcome results